

Buprenorphine Waiver Training, Monday, Feb. 4, 2019, 4:00-8:30 PM
Umpqua Valley Arts Association, 1624 West Harvard Avenue, Roseburg, Oregon

Tuition: No Cost

To register, please visit:

<https://www.eventbrite.com/e/buprenorphine-waiver-training-roseburg-oregon-tickets-54155687118>

What is Buprenorphine Waiver Training?

The Providers Clinical Support System Medication Assisted Treatment (PCSS-MAT) Half and Half Medication Assisted Treatment waiver training course provides an overview of the FDA-approved medications – buprenorphine, naltrexone, and methadone – prescribed for the treatment of opiate use disorder (OUD). This course provides the required training for physicians, Physicians Assistants (PAs) and Advanced Practice Registered Nurses (APRNs) to prescribe buprenorphine in office-based settings for the treatment of OUD, and training for other practitioners involved in the treatment of OUD patients. The course provides an overview of prevention, identification, and treatment of substance use disorders emphasizing OUD. Residents may take the course and apply for their waiver when they receive their DEA license.

The Half and Half Course

The course is provided in a “Half and Half” format, which means the first part is taken in person and the second part, for physicians, PAs and APRNs, is completed on-line. The 4.5 hour in-person portion of the course is open to interested practitioners who are involved in serving patients receiving medication assisted treatment for OUD (nurses, counselors, social workers, pharmacists, etc.), as well as physicians, PAs, and APRNs. The 3.5 hour on-line portion completes the 8-hour training requirement for physicians. For PAs and APRNs, an additional 16 hours training is required to meet the 24 hour training requirement for the waiver (see <https://pcssnow.org/education-training/mat-training/>). After completing the in-person training, eligible participants will be emailed instructions for the on-line portion of the course. Those who have successfully completed the course (both on-line and live) are eligible to apply to the US Substance Abuse and Mental Health Services Administration (SAMHSA) to obtain a waiver to prescribe buprenorphine. PCSS-MAT urges all participants who complete the course to submit a Notice of Intent Form to SAMHSA, available on-line and provided by mail following the training.

PCSS-MAT has a comprehensive library of materials available at no cost, created to give providers confidence in preventing and treating these medical disorders. PCSS-MAT also provides a no-cost clinical coaching/mentoring program to help primary care providers in their ability to address these concerns.

CME Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of OHSU and AAAP. OHSU is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

OHSU School of Medicine designates this (first “half” of the course) live activity for a maximum of **4.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician/APP Participation in the Learning Process

Physician/APPs will only be awarded **4.5 AMA PRA Category 1 Credits™** after completing the “second” half of the training. To obtain a buprenorphine training certificate of completion you must complete BOTH halves of the training and receive a minimum cumulative score of 75% on the examination.

Disclosure of Support

Funding for this initiative was made possible by the SAMHSA-funded American Association of Addiction Psychiatry’s Provider Clinical Support Service (PCSS) for Medication Assisted Treatment. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. Partial funding for this program comes from SAMHSA to the Oregon Health Authority to expand MAT capacity across Oregon. Additional funding is also provided through OHSU and the Western States Node of the National Institute on Drug Abuse Clinical Trials Network.